chronic myeloid leukemia cytogenetic methods and applications for diagnosis and treatment
báo cáo khoa học: "P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia" pps
... responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing ... Diseases Fund Writing and editorial support were provided by Erin Nagle and Josh Collis and funded by Bristol-Myers Squibb Company 16 References 10 11 12 Sawyers CL: Chronic myeloid leukemia N Engl ... MWN: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 2007, 110:2242-2249 Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J,...
- 9
- 300
- 0
báo cáo khoa học: "Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia" pot
... Page of and post two courses of chemotherapy (CT) for Ph-negative ALL, respectively and 72°C for min, and a final elongation at 72° C Then, the products were stored at 4°C Cytogenetic, FISH and RT-PCR ... BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia Leukemia 1999, 13:126-129 Ohtsuka ... lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia Journal of Hematology & Oncology 2010 3:14 Submit your next manuscript to BioMed Central and...
- 7
- 322
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 1) ppsx
... Acute Myeloid Leukemia Incidence The incidence of acute myeloid leukemia (AML) is ~3.7 per 100,000 people per year, and the age-adjusted incidence is higher ... 4–6 years after exposure, and affected individuals have aberrations in chromosomes and Topoisomerase II inhibitor–associated leukemias occur 1–3 years after exposure, and affected individuals ... Chemical and Other Exposures Exposure to benzene, a solvent used in the chemical, plastic, rubber, and pharmaceutical industries, is associated with an increased incidence of AML Smoking and exposure...
- 5
- 300
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 2) pot
... myelomonocytic leukemia Acute monoblastic and monocytic leukemia Acute erythroid leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis with myelofibrosis Myeloid sarcoma ... differentiated leukemia 5% M1: Myeloblastic leukemia without maturation 20% M2: Myeloblastic leukemia with maturation 30% M3: Hypergranular promyelocytic leukemia 10% M4: Myelomonocytic leukemia 20% ... Monocytic leukemia 10% M6: Erythroleukemia (DiGuglielmo's disease) 4% M7: Megakaryoblastic leukemia 1% a ES Jaffe et al: World Health Organization Classification of Tumours Lyon, IARC Press, 2001 b Diagnosis...
- 5
- 261
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 3) pps
... step and forces the clinician to correctly identify the entity and tailor treatment( s) accordingly Chromosomal Analyses Chromosomal analysis of the leukemic cell provides the most important pretreatment ... increased proliferation and antiapoptotic signals to the myeloid progenitor cell Presence of FLT3 ITD in patients with normal cytogenetics predicts for short remission duration and inferior survival ... nucleophosmin gene (NPM1) and C/EBP α that are associated with improved treatment outcome In contrast, overexpression of genes such as brain and acute leukemia, cytoplasmic (BAALC) predicts for poor outcome...
- 5
- 250
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 4) pps
... leukemic blasts at diagnosis is characteristic of the monocytic subtypes and those with 11q23 chromosomal abnormalities Hematologic Findings Anemia is usually present at diagnosis and can be severe ... when they are, myeloid lineage is virtually certain (Fig 104-1) Poor neutrophil function may be noted by impaired phagocytosis and migration and morphologically by abnormal lobulation and deficient ... splenomegaly, hepatomegaly, lymphadenopathy, sternal tenderness, and evidence of infection and hemorrhage are often found at diagnosis Significant gastrointestinal bleeding, intrapulmonary hemorrhage,...
- 5
- 281
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 5) docx
... hepatic, and renal systems Factors that have prognostic significance, either for achieving complete remission (CR) or for predicting the duration of CR, should also be assessed before initiating treatment ... all patients and cryopreserved for future use as new tests and therapeutics become available All patients should be evaluated for infection Table 104-2 Initial Diagnostic Evaluation and Management ... HSV-1, varicella zoster) RBC type and screen HLA typing of patient, siblings, and parents for potential allogeneic SCT Bone marrow aspirate and biopsy (morphology, cytogenetics, flow cytometry, molecular...
- 6
- 255
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6) pps
... emphasizes the importance of cytogenetic as well as the previously discussed molecular assessment of the leukemia cells at diagnosis and relevance of storing samples for potential later use A prolonged ... system bleeding and pulmonary leukostasis contribute to poor outcome with initial therapy In addition to pretreatment variables such as age, cytogenetics, and leukocyte count, several treatment factors ... more resistant disease Chronic and intercurrent diseases impair tolerance to rigorous therapy; acute medical problems at diagnosis reduce the likelihood of survival Performance status, independent...
- 5
- 299
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 7) pot
... Figure 104-2 Flow chart for the therapy of newly diagnosed acute myeloid leukemia For all forms of AML except acute promyelocytic leukemia (APL), standard therapy includes a 7-day continuous ... continuous intravenous infusion for days Anthracycline therapy generally consists of daunorubicin intravenously on days 1, 2, and (the and regimen) Treatment with idarubicin for days in conjunction with ... synthesis and thereby overcome resistance to standard-dose cytarabine In two randomized studies, high-dose cytarabine with an anthracycline produced CR rates similar to those achieved with standard and...
- 5
- 284
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 8) pdf
... hospitalizations In most randomized studies, both G-CSF and GM-CSF have failed to improve the CR rate, disease-free survival, or overall survival Although receptors for both G-CSF and GM-CSF are present ... (CMV)-negative blood products should be used for CMVseronegative patients who are potential candidates for allogeneic SCT Leukodepleted products are also effective for these patients if CMV-negative products ... diagnosed AML have been stabilized They should be used thereafter for administration of intravenous medications and transfusions, as well as for blood drawing Antibiotic-impregnated catheters should...
- 5
- 240
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 9) pptx
... cytarabine is more effective than standard-dose cytarabine The Cancer and Leukemia Group B (CALGB), for example, compared the duration of CR in patients randomly assigned postremission to four ... days 1, 3, and 5), intermediate (400 mg/m2 for days by continuous infusion), or standard (100 mg/m2 per day for days by continuous infusion) doses of cytarabine A dose-response effect for cytarabine ... prolonged CR and increased the fraction cured in patients with favorable [t(8;21) and inv(16)] and normal cytogenetics, but it had no significant effect on patients with other abnormal karyotypes For...
- 5
- 289
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 11) pps
... abelson murine leukemia virus) gene located on chromosome 9q34 Untreated, the disease is characterized by the inevitable transition from a chronic phase to an accelerated phase and on to blast ... cytotoxic drugs has been found, and no evidence suggests a viral etiology In the pre-imatinib era, cigarette smoking accelerated the progression to blast crisis and therefore adversely affected survival ... required for blastic transformation Finally, CML that develops resistance to imatinib is at an increased risk of progressing to accelerated/blast crisis Multiple pathways to disease transformation...
- 5
- 295
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 13) pptx
... molecular remission and cure A proposed imatinib treatment algorithm for the newly diagnosed CML patient is presented in Table 104-4 Table 104-4 Imatinib Treatment Milestones for Newly Diagnosed ... remissionb,d No cytogenetic remission Any cytogenetic remissionc 12 Minore or no cytogenetic Completeb,f partialc,g remission or cytogenetic remission 18 Partial, minor, or no cytogenetic remission ... Anytime Complete cytogenetic remissionb Loss of previously achieved hematologic, cytogenetic, or molecular remission a Nutritional Comprehensive Cancer Network, Chronic myelogenous leukemia b Denotes...
- 5
- 224
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 14) pot
... transplantation For all other groups, patients receiving BMT from unrelated donors have higher rates of graft failure and acute and chronic GVHD and prolonged convalescence after treatment, compared ... in the chronic phase achieves 5-year disease-free survival in 40–70% of patients, with a 25% relapse rate BMT from an HLA-matched unrelated donor in chronic phase
- 5
- 223
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 15) ppt
... CML Specific milestones have been developed for chronicphase CML patients (Table 104-4) For example, chronic- phase CML patients who not achieve any cytogenetic remission following six months of ... the treatment algorithm of CML For example, patients who not achieve any cytogenetic remission at six months on imatinib will now be offered either dasatinib or SCT IFN-α, though FDAapproved for ... 98% The 5-year PFS for patients not achieving complete cytogenetic remission at 18 months was 87% These results have led to a consensus that molecular responses can be used as a treatment goal in...
- 6
- 219
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 16) pptx
... of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia Blood 105:3019, 2005 [PMID: 15604216] Tallman MS et al: Drug therapy for acute myeloid leukemia Blood ... approaches in chronic myeloid leukemia J Clin Oncol 23:6316, 2005 [PMID: 16155014] Hughes TP et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors Review and recommendations ... kinase inhibitors Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108:28, 2006 [PMID:...
- 7
- 285
- 0
báo cáo khoa học: "First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib" ppsx
... Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia Blood 2009, 114:4933-4938 Saglio G, Baccarani M: First-line therapy for chronic myeloid leukemia: new horizons and an update ... cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice Leukemia 2009, 23:1446-1454 Quintas-Cardama A, Cortes J: Omacetaxine mepesuccinate–a semisynthetic formulation ... with interferon and low-dose cytarabine for newly diagnosed chronic- phase chronic myeloid leukemia N Engl J Med 2003, 348:994-1004 Masiello D, Gorospe G, Yang AS: The occurrence and management...
- 10
- 478
- 2
Báo cáo sinh học: "Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells" pptx
... (anti-sense) for b-actin The PCR conditions were as follows: for c-IAP-1 and XIAP, 94°C for min, 62°C for min, and 72°C for min; for Bcl-2, 94°C for 30 s, 62°C for 30 s, 72°C for 10 s; and for b-actin: ... both dose- and time-dependent manners (Figure 2B, C, D) The IC 50 values at 24, 48, 72, and 96 h were 230.5, 86.9, 60.0, and 35.7 μM for KG1a, 68.5, 46.6, 28.8, and 23.5 μM for Kasumi-1, and 58.3, ... μg/ml, and 80 μM to 0.4 μg/ml, respectively) for 48 h, as shown in Figure 5A, B and Table S1 (Additional file 3) Both CalcuSyn software and Jin’s formula were used to determine synergy, and the...
- 15
- 415
- 0
Tìm thêm: hệ việt nam nhật bản và sức hấp dẫn của tiếng nhật tại việt nam khảo sát các chuẩn giảng dạy tiếng nhật từ góc độ lí thuyết và thực tiễn khảo sát chương trình đào tạo của các đơn vị đào tạo tại nhật bản xác định thời lượng học về mặt lí thuyết và thực tế tiến hành xây dựng chương trình đào tạo dành cho đối tượng không chuyên ngữ tại việt nam điều tra với đối tượng sinh viên học tiếng nhật không chuyên ngữ1 khảo sát thực tế giảng dạy tiếng nhật không chuyên ngữ tại việt nam khảo sát các chương trình đào tạo theo những bộ giáo trình tiêu biểu phát huy những thành tựu công nghệ mới nhất được áp dụng vào công tác dạy và học ngoại ngữ mở máy động cơ rôto dây quấn các đặc tính của động cơ điện không đồng bộ hệ số công suất cosp fi p2 đặc tuyến hiệu suất h fi p2 đặc tuyến mômen quay m fi p2 đặc tuyến tốc độ rôto n fi p2 đặc tuyến dòng điện stato i1 fi p2 sự cần thiết phải đầu tư xây dựng nhà máy thông tin liên lạc và các dịch vụ từ bảng 3 1 ta thấy ngoài hai thành phần chủ yếu và chiếm tỷ lệ cao nhất là tinh bột và cacbonhydrat trong hạt gạo tẻ còn chứa đường cellulose hemicellulose chỉ tiêu chất lượng 9 tr 25